- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | EQL PHARMA AB: Nomination committee for the 2026 Annual General Meeting | 1 | Cision News | ||
| 03.02. | EQL Pharma AB: Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026 | 98 | GlobeNewswire (Europe) | Today, on 3 February 2026, the extraordinary general meeting was held in EQL Pharma AB. A summary of the adopted resolution follows below.
Resolution on implementation of a long-term incentive program... ► Artikel lesen | |
| 03.02. | EQL Pharma AB: Interim Report April - December 2025 | 88 | GlobeNewswire (Europe) | During the quarter, sales rose to SEK 118.9 million, an increase of 29% from SEK 92.2 million in the previous year. This represents a new record quarter for EQL
Comments from the CEO
The third quarter... ► Artikel lesen | |
| 15.01. | Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26 | 3 | Cision News | ||
| 07.01. | Notice of extraordinary general meeting in EQL Pharma AB | 1 | Cision News | ||
| EQL PHARMA Aktie jetzt für 0€ handeln | |||||
| 04.12.25 | EQL Pharma AB: EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO) | 285 | GlobeNewswire (Europe) | As previously announced, EQL Pharma has decided to strengthen its abilities in international commercial affairs, as a part of its European expansion. The Company has recruited Anne D. Jensen for this... ► Artikel lesen | |
| 03.12.25 | EQL Pharma AB: EQL Pharma recruits Allan Sylvest Aasberg as new Chief Financial Officer (CFO) | 127 | GlobeNewswire (Europe) | EQL Pharma strengthens and re-organizes its Finance Function to put more emphasis on business control and capital allocation. Our current CFO, Anna Jönsson, will take on the role as Head of Accounting.... ► Artikel lesen | |
| 17.11.25 | EQL Pharma AB (publ) publishes prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm | 13 | Cision News | ||
| 14.11.25 | EQL Pharma AB: Methenamine Hippurate (branded as Cystohipp©) have gained marketing approval in Germany | 539 | GlobeNewswire (Europe) | EQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in Germany, where it is to be provided to patients by EQL's license partner Dr Pfleger under the EQL... ► Artikel lesen | |
| 05.11.25 | EQL Pharma AB: Interim Report April - September 2025 | 132 | GlobeNewswire (Europe) | A tough quarter for EQL
Comments from the CEO
The second quarter of 2025/26 was marked by unforeseen delivery disruptions, resulting in sales growth of only 1%. The EBITDA margin, which was naturally... ► Artikel lesen | |
| 22.10.25 | Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2025/26 | 3 | Cision News | ||
| 06.10.25 | EQL Pharma AB: EQL Pharma in process of recruiting new Chief Commercial Officer (CCO) | 151 | GlobeNewswire (Europe) | EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his position.... ► Artikel lesen | |
| 30.09.25 | Change in number of shares and votes in EQL Pharma AB | 1 | Cision News | ||
| 23.09.25 | EQL PHARMA AB: Mellozzan (melatonin) launched in the UK | 1 | Cision News | ||
| 22.09.25 | EQL Pharma AB: Delivery delays mean that the second quarter and thus the full year 2025/26 will be weaker than expected | 263 | GlobeNewswire (Europe) | EQL Pharma has experienced delays in deliveries from several suppliers during the second quarter, resulting in lost sales during the quarter. Deliveries will come, but the lost sales cannot be made... ► Artikel lesen | |
| 11.09.25 | EQL PHARMA AB: Mellozzan (melatonin) approved in Turkey | 2 | Cision News | ||
| 05.09.25 | Exercise of warrants in EQL Pharma AB's incentive programs | 1 | Cision News | ||
| 25.08.25 | EQL Pharma AB: EQL Pharma's Chief Commercial Officer (CCO) sells shares to buy apartment for daughter | 198 | GlobeNewswire (Europe) | EQL Pharma's Chief Commercial Officer (CCO) Alexander Brising has recently sold shares for approximately SEK 2.1 million to pay for an apartment for his daughter who is starting university. "Not a decision... ► Artikel lesen | |
| 21.08.25 | EQL Pharma AB: Bulletin from the annual general meeting in EQL Pharma AB on 21 August 2025 | 209 | GlobeNewswire (Europe) | Today, on 21 August 2025, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and allocation of the company's... ► Artikel lesen | |
| 08.08.25 | EQL Pharma AB: Interim Report April - June 2025 | 410 | GlobeNewswire (Europe) | A strong start to the year - Sales and operating profit growing, good progress in business development
April - June 2025
Consolidated sales during the first quarter, April to June amounted to SEK... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 414,00 | -0,46 % | Vertex Pharmaceuticals Inc. Reports Rise In Q4 Bottom Line | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported earnings for its fourth quarter that Increases, from last yearThe company's earnings came in at $1.191 billion... ► Artikel lesen | |
| UNITED THERAPEUTICS | 440,50 | +0,25 % | United Therapeutics auf der TD Cowen Konferenz: Einblicke in die strategische Wachstumsplanung | ||
| CATALYST PHARMACEUTICALS | 19,730 | -3,43 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| INDIVIOR PHARMACEUTICALS | 26,820 | -1,32 % | Indivior Pharmaceuticals Inc.: Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results | Generated Record Quarterly and Full-Year Total SUBLOCADE Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly... ► Artikel lesen | |
| CAMURUS | 43,560 | -3,67 % | CAMURUS AB: Change in number of shares and votes in Camurus | ||
| BAYER | 38,620 | -4,90 % | MustGrow Biologics und die Partnerschaft mit Bayer: Darum steht die Aktie erst am Anfang | Die globale Landwirtschaft steht vor einem Paradox. Sie muss mehr Menschen ernähren, aber mit weniger chemischen Mitteln. Weltweit sind in 162 Ländern inzwischen 460 Pestizide verboten oder eingeschränkt.... ► Artikel lesen | |
| NOVO NORDISK | 31,145 | -3,19 % | Hims & Hers nach Preisattacke auf Novo Nordisk mit Zahlen: Aktie rauscht erneut in den Keller | Die US-amerikanische Telemedizin-Plattform Hims & Hers hat am Montag nach Börsenschluss die Zahlen für das vierte Quartal respektive Gesamtjahr 2025 vorgelegt. Überschattet werden die Ergebnisse und... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 15,060 | 0,00 % | Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies | Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform
Lead candidates ATR 1072... ► Artikel lesen | |
| MERCK KGAA | 122,65 | -2,85 % | Big Blue IBM, Fastly & Merck KGaA - Was sagen Charts UND Fundamentaldaten wirklich? | ||
| HARROW | 53,29 | 0,00 % | Harrow Q4 Net Income Slips Despite 33% Revenue Growth; Issues FY26 Guidance; Stock Down | ||
| PFIZER | 23,135 | -0,73 % | Amt warnt vor Honigpaste mit verstecktem Viagra-Wirkstoff | TÜBINGEN (dpa-AFX) - Das Landratsamt Tübingen warnt vor dem Verzehr einer bei Amazon verkauften Honigpaste - weil ein verstecktes Potenzmittel drin ist. Das Nahrungsergänzungsmittel "Lotus Mixed Herbal... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,225 | 0,00 % | Aquestive Therapeutics, Inc. - 8-K, Current Report | ||
| GENERATE BIOMEDICINES | 12,420 | -2,66 % | Generate Biomedicines Prices IPO At $16/shr | WASHINGTON (dpa-AFX) - Generate Biomedicines, Inc. (GENB) on Thursday priced its initial public offering of 25,000,000 shares of stock at $16 per share, raising gross proceeds of $400 million.The... ► Artikel lesen | |
| GSK | 24,470 | -1,85 % | GSK kauft kanadische 35Pharma für 950 Millionen US-Dollar | DJ GSK kauft kanadische 35Pharma für 950 Millionen US-Dollar
Von Sarah Sloat
DOW JONES--GSK hat die Übernahme des Biopharma-Unternehmens 35Pharma für 950 Millionen US-Dollar vereinbart. 35Pharma... ► Artikel lesen | |
| SANOFI | 80,37 | -1,41 % | Regeneron und Sanofi erhalten Empfehlung für erweiterte Dupixent-Zulassung | DJ Regeneron und Sanofi erhalten Empfehlung für erweiterte Dupixent-Zulassung
Von Colin Kellaher
DOW JONES--Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur... ► Artikel lesen |
Das Unternehmen EQL PHARMA AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,150 (-2,84 %) liegt der Kurs bei 5,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EQL PHARMA AB finden Sie auf Wallstreet Online.